• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » EstroGel (estradiol gel 0.06%)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

EstroGel (estradiol gel 0.06%)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    EstroGel is a topical gel containing 0.06% estradiol in an absorptive hydroalcoholic gel base, formulated to provide a controlled release of the hormone. It is designed to treat symptoms associated with menopause.

    It is specifically indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, including hot flashes. It is also indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause, especially when the atrophy is concurrent to vasomotor symptoms.

    The recommended topical dose of EstroGel is 1.25 g once daily, delivered via metered pump. Recommended application is to the posterior surface of the arm, from the back of the wrist to the shoulder.

    Clinical Results

    FDA approval of EstroGel for the treatment of monopausal vasomotor symptoms was based on a double-blind, placebo-controlled study enrolling 145 women between 29 and 67 years of age. Subjects received either 1.25g EstroGel (n=72) or placebo (n=73) once daily for 12 weeks. Primary endpoint efficacies, measured by reduction in the occurrence of moderate-to-severe hot flashes and reduction in severity of hot flashes, were assessed at 4, 8, and 12 weeks. Results showed that EstroGel produced a statistically significant decrease in both the number and severity of hot flashes at 4 and 12 weeks (reduction at 8 weeks was not significant). Specifically, at 4 weeks, subjects receiving EstroGel experienced 0.85 fewer hot flashes per day, and a reduction in severity score of 0.32; at 12 weeks, EstroGel subjects experienced 1.71 fewer hot flashes and a severity score reduction of 0.49.

    FDA approval of EstroGel for the treatment of vulvar and vaginal atrophy was based on results of vagina wall cytology examinations performed on all subjects at 12 weeks. A significant increase in superficial epithelial cells was observed for the EstroGel group; no significant increase was seen among the placebo group.

    Side Effects

    Adverse events associated with the use of EstroGel may include (but are not limited to) the following:

    • Infection
    • Abdominal Pain
    • Diarrhea
    • Weight Gain
    • Pap Smear: Suspiscious
    • Metrorrhagia
    • Vaginitis
    • Pruritus

    Mechanism of Action

    EstroGel supplies systemic estradiol, the primary estrogenic hormone secreted by the human ovaries, which is lost during and following menopause. Estradiol binds to widely distributed nuclear receptors in estrogen sensitive tissues. It also acts to inhibit the pituitary release of leutenizing hormone and follicle stimulating hormone via negative feedback loop (elevated levels of these hormones are customarily observed in postmenopausal women).

    Literature References

    Archer DF; EstroGel Study Group. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2003 Nov-Dec;10(6):516-21.

    Brennan JJ, Lu Z, Whitman M, Stafiniak P, van der Hoop RG. Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women. Therapeutic Drug Monitoring. 2001 Apr;23(2):134-8.

    Additional Information

    For additional information regarding EstroGel or symptoms of menopause, please contact the EstroGel Web Site

    Approval Date: 2004-04-01
    Company Name: Solvay Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing